What is the clinical evidence from this study?

Study design: Cohort. Population: Acute ischemic stroke and cerebral aneurysms (n=67). Intervention: Cangrelor. Primary outcome: 24-hour stent patency.

What does this research mean for the field?

Intravenous cangrelor provides effective and safe platelet inhibition during emergency neuroendovascular stenting, achieving high 24-hour stent patency with low bleeding complication rates in acute ischemic stroke and cerebral aneurysm patients. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To evaluate the efficacy and safety of the intravenous P2Y12 inhibitor cangrelor in patients requiring emergency stent placement for acute ischemic stroke or cerebral aneurysms.

August 19, 2026Neuroradiology

Use of cangrelor in neuroendovascular interventions: real-world evidence from a single-center cohort

View Full Paper

Ask AI

Bookmark

Key result

Cangrelor achieves ~98% 24-hour stent patency during emergency neuroendovascular stenting for acute ischemic stroke.

n=67

Why the study?

Emergency neurovascular stenting requires immediate and reliable platelet inhibition, and cangrelor may offer advantages over conventional regimens in acute ischemic stroke and cerebral aneurysms.

Does cangrelor provide effective stent patency and safety in patients with acute ischemic stroke or cerebral aneurysms requiring emergency stenting?

Key Points

To evaluate the efficacy and safety of the intravenous P2Y12 inhibitor cangrelor in patients requiring emergency stent placement for acute ischemic stroke or cerebral aneurysms.
Retrospective single-center review of 67 consecutive emergency stenting patients (43 with acute ischemic stroke and 24 with cervical or cerebral aneurysms) treated between January 2021 and March 2026.
All patients received a full-dose cangrelor regimen (30 µg/kg bolus followed by 4 µg/kg/min infusion for 12–24 hours) before transitioning to oral aspirin and ticagrelor.
Primary endpoints evaluated were 24-hour stent patency for efficacy and hemorrhagic complications for safety.
Stent patency at 24 hours was 97.7% (n=42/43) in the acute ischemic stroke cohort and 100% (n=23/23) in the aneurysm cohort.
Hemorrhagic complications occurred in 7.0% (n=3/43) of stroke patients and 4.3% (n=1/23) of aneurysm patients, with the single aneurysm bleed linked to intraprocedural perforation.
Good functional outcomes at discharge (mRS ≤ 2) occurred in 46.9% (n=15/32) of stroke patients and 79.2% (n=19/24) of aneurysm patients, with overall mortality of 9.1% (n=6/66).

Study Design

Type

Cohort (n=67)

Multicenter

Structured PICO

Does cangrelor provide effective stent patency and safety in patients with acute ischemic stroke or cerebral aneurysms requiring emergency stenting?

Population

67 patients with acute ischemic stroke or cerebral aneurysms requiring emergency stent implantation who received cangrelor.

Exposure

Cangrelor full dose (bolus 30 µg/kg followed by infusion 4 µg/kg/min for 12-24 h), transitioned to aspirin and ticagrelor

Outcome

24-hour stent patency (primary efficacy) and hemorrhagic complications (primary safety)surrogate

In a real-world cohort, cangrelor provided effective peri-procedural platelet inhibition with high stent patency and low bleeding rates for neurovascular emergencies requiring emergency stenting.

Limitations

Exploratory nature
Clinical heterogeneity between the cohorts
Retrospective design
Single-center cohort
Clinical heterogeneity between cohorts
Need for larger prospective studies (retrospective design)

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Cangrelor may offer rapid platelet inhibition for neurovascular stenting; leaves open its efficacy and safety versus standard regimens.

Cite This Study

Pelle et al. (2026) conducted a cohort in Acute ischemic stroke and cerebral aneurysms (n=67). Cangrelor was evaluated on 24-hour stent patency. Cangrelor administration during emergency neuroendovascular stenting achieved 24-hour stent patency in 97.7% of acute ischemic stroke patients and 100% of aneurysm patients.

synapsesocial.com/papers/6a858b9903308d306e2d8072 https://doi.org/10.1007/s00234-026-04150-1

View Full Paper

Ask AI

Bookmark

Use of cangrelor in neuroendovascular interventions: real-world evidence from a single-center cohort

Key Points

Study Design

Structured PICO

Limitations

Discussion

Implication

Cite This Study

Use of cangrelor in neuroendovascular interventions: real-world evidence from a single-center cohort

Key Points

Study Design

Structured PICO

Limitations

Discussion

Implication

Cite This Study

Also Consider

Also Consider